NASDAQ:UTHR - United Therapeutics Stock Price, Price Target & More

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

United Therapeutics declared that its board has initiated a share buyback plan on Sunday, June 4th 2017, which permits the company to repurchase $250,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 4.6% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's management believes its shares are undervalued.

United Therapeutics Co. (NASDAQ:UTHR) issued its quarterly earnings data on Wednesday, May, 2nd. The biotechnology company reported $5.57 EPS for the quarter, beating analysts' consensus estimates of $3.62 by $1.95. The biotechnology company had revenue of $389.20 million for the quarter, compared to analyst estimates of $393.96 million. United Therapeutics had a return on equity of 26.68% and a net margin of 27.74%. The firm's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period in the prior year, the business posted $3.61 earnings per share. View United Therapeutics' Earnings History.

United Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for United Therapeutics.

8 Wall Street analysts have issued 1 year price targets for United Therapeutics' shares. Their predictions range from $95.00 to $232.00. On average, they anticipate United Therapeutics' share price to reach $130.75 in the next twelve months. View Analyst Ratings for United Therapeutics.

Some companies that are related to United Therapeutics include Mylan (MYL), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), Jazz Pharmaceuticals (JAZZ), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals Intl (VRX), BeiGene (BGNE), Genmab A/S (GNMSF), Alkermes (ALKS) and SAGE Therapeutics (SAGE).

Headlines about UTHR stock have been trending somewhat positive on Wednesday, Accern reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. United Therapeutics earned a news impact score of 0.24 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 46.50 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

United Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (11.28%), Palo Alto Investors LP (3.73%), Old Mutual Global Investors UK Ltd. (2.21%), Dimensional Fund Advisors LP (2.20%), FIL Ltd (1.48%) and Thompson Siegel & Walmsley LLC (1.25%). Company insiders that own United Therapeutics stock include Christopher Causey, Christopher Patusky, Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Institutional Ownership Trends for United Therapeutics.

UTHR stock was sold by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Wells Fargo & Company MN, Royal Bank of Canada, Millennium Management LLC, BNP Paribas Arbitrage SA, Thompson Siegel & Walmsley LLC, Swiss National Bank and State of Tennessee Treasury Department. Company insiders that have sold United Therapeutics company stock in the last year include Christopher Causey, Judy D Olian, Martine A Rothblatt, Raymond Dwek and Richard Giltner. View Insider Buying and Selling for United Therapeutics.

UTHR stock was purchased by a variety of institutional investors in the last quarter, including LSV Asset Management, BlackRock Inc., Mackay Shields LLC, Prudential Financial Inc., Robeco Institutional Asset Management B.V., UBS Group AG, Senzar Asset Management LLC and Ontario Teachers Pension Plan Board. View Insider Buying and Selling for United Therapeutics.

Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of UTHR stock can currently be purchased for approximately $117.49.

United Therapeutics has a market capitalization of $5.11 billion and generates $1.73 billion in revenue each year. The biotechnology company earns $417.90 million in net income (profit) each year or $10.89 on an earnings per share basis. United Therapeutics employs 800 workers across the globe.

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]